Bradley & Co. Private Wealth Management LLC Makes New Investment in Standard BioTools Inc. (NASDAQ:LAB)

Bradley & Co. Private Wealth Management LLC acquired a new stake in shares of Standard BioTools Inc. (NASDAQ:LAB) during the fourth quarter, HoldingsChannel reports. The firm acquired 179,364 shares of the company’s stock, valued at approximately $314,000.

A number of other large investors have also modified their holdings of the company. JPMorgan Chase & Co. raised its position in Standard BioTools by 7.7% in the third quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock worth $270,000 after purchasing an additional 9,995 shares in the last quarter. Wolverine Trading LLC acquired a new stake in Standard BioTools during the third quarter valued at approximately $27,000. Nisa Investment Advisors LLC grew its stake in shares of Standard BioTools by 433.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after purchasing an additional 14,732 shares during the period. Creative Planning acquired a new position in shares of Standard BioTools in the 3rd quarter worth approximately $39,000. Finally, Simon Quick Advisors LLC bought a new position in shares of Standard BioTools during the 4th quarter worth approximately $54,000. 53.74% of the stock is currently owned by institutional investors and hedge funds.

Standard BioTools Price Performance

Shares of LAB opened at $1.27 on Wednesday. The company has a market capitalization of $470.91 million, a P/E ratio of -1.78 and a beta of 1.57. Standard BioTools Inc. has a one year low of $1.17 and a one year high of $3.04. The business’s 50 day simple moving average is $1.65 and its 200-day simple moving average is $1.81.

Analysts Set New Price Targets

Separately, TD Cowen lowered their price target on Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a research report on Thursday, October 31st.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.